{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:47:17Z","timestamp":1781560037947,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.clinthera.2009.10.015","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T09:48:11Z","timestamp":1258451291000},"page":"2189-2203","source":"Crossref","is-referenced-by-count":11,"title":["Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea"],"prefix":"10.1016","volume":"31","author":[{"given":"Danny","family":"Liew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Kyoung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.10.015_bib1","series-title":"The Third Korean National Health and Nutrition Examination Survey (KNHNES III)","year":"2005"},{"key":"10.1016\/j.clinthera.2009.10.015_bib4","series-title":"National Health Insurance Statistical Yearbook","year":"2005"},{"key":"10.1016\/j.clinthera.2009.10.015_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10557-007-6032-4","article-title":"The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease","volume":"21","author":"Kostis","year":"2007","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.clinthera.2009.10.015_bib8","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/0091270007307879","article-title":"A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: The Respond trial","volume":"47","author":"Preston","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.10.015_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1524-4733.2007.00250.x","article-title":"An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy","volume":"11","author":"Annemans","year":"2008","journal-title":"Value Health."},{"key":"10.1016\/j.clinthera.2009.10.015_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1015323700206","article-title":"The economic efficiency of amlodipine in the treatment of coronary atherosclerosis\u2014an analysis based on the PREVENT study","volume":"16","author":"Cathomas","year":"2002","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.clinthera.2009.10.015_bib12","first-page":"71","article-title":"Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada","volume":"20","author":"Coyle","year":"2004","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.clinthera.2009.10.015_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.phrs.2006.04.002","article-title":"The pharmacoeconomic impact of amlodipine use on coronary artery disease","volume":"54","author":"De Portu","year":"2006","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.clinthera.2009.10.015_bib14","first-page":"82","article-title":"A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension","volume":"14","author":"Doyle","year":"2001","journal-title":"Manag Care Interface."},{"key":"10.1016\/j.clinthera.2009.10.015_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1742-1241.2002.tb11200.x","article-title":"A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden","volume":"56","author":"Doyle","year":"2002","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.clinthera.2009.10.015_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11606-008-0515-2","article-title":"Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: An analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"23","author":"Heidenreich","year":"2008","journal-title":"J Gen Intern Med."},{"key":"10.1016\/j.clinthera.2009.10.015_bib17","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1136\/hrt.2007.127217","article-title":"Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen","volume":"94","author":"Lindgren","year":"2008","journal-title":"Heart."},{"key":"10.1016\/j.clinthera.2009.10.015_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.phrs.2005.10.002","article-title":"Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA","volume":"53","author":"Rossetti","year":"2006","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.clinthera.2009.10.015_bib19","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.2337\/diacare.26.6.1796","article-title":"Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes","volume":"26","author":"Brandle","year":"2003","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.10.015_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00019053-200321001-00003","article-title":"A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom","volume":"21","author":"Buller","year":"2003","journal-title":"Pharmaco Economics."},{"key":"10.1016\/j.clinthera.2009.10.015_bib21","first-page":"e179","article-title":"A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada","volume":"11","author":"Casciano","year":"2004","journal-title":"Can J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.10.015_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1592\/phco.25.2.270.56946","article-title":"Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: Clinical implications for therapeutic selection","volume":"25","author":"Chong","year":"2005","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2009.10.015_bib23","first-page":"188","article-title":"Epidemiology and economics of statin use","volume":"101","author":"Feely","year":"2008","journal-title":"Ir Med J."},{"key":"10.1016\/j.clinthera.2009.10.015_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10198-003-0222-1","article-title":"A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain","volume":"5","author":"G\u00f3mez-Gerique","year":"2004","journal-title":"Eur J Health Econ."},{"key":"10.1016\/j.clinthera.2009.10.015_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1592\/phco.20.9.819.35197","article-title":"Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study","volume":"20","author":"Hilleman","year":"2000","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2009.10.015_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0149-2918(07)80089-0","article-title":"A model for assessing the costeffectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets","volume":"29","author":"Lachaine","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2009.10.015_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.acvd.2008.05.003","article-title":"Costeffectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: A French adaptation of CARDS","volume":"101","author":"Lafuma","year":"2008","journal-title":"Arch Cardiovasc Dis."},{"key":"10.1016\/j.clinthera.2009.10.015_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00149831-200502000-00005","article-title":"Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: An economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA)","volume":"12","author":"Lindgren","year":"2005","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"10.1016\/j.clinthera.2009.10.015_bib29","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehm020","article-title":"Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin","volume":"28","author":"Lindgren","year":"2007","journal-title":"EurHeartJ."},{"issue":"Suppl 15","key":"10.1016\/j.clinthera.2009.10.015_bib30","first-page":"S412","article-title":"Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice","volume":"12","author":"Ohsfeldt","year":"2006","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.clinthera.2009.10.015_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijcard.2003.06.012","article-title":"A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden","volume":"96","author":"Olsson","year":"2004","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.clinthera.2009.10.015_bib32","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1185\/03007990802144705","article-title":"Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men","volume":"24","author":"Peura","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2009.10.015_bib33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1524-4733.2007.00224.x","article-title":"Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal","volume":"11","author":"Pinto","year":"2008","journal-title":"Value Health."},{"key":"10.1016\/j.clinthera.2009.10.015_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00129784-200606030-00005","article-title":"Cost-effectiveness analysis of cholesterol-lowering therapies in Spain","volume":"6","author":"Plans-Rubi\u00f3","year":"2006","journal-title":"Am J Cardiovasc Drugs."},{"key":"10.1016\/j.clinthera.2009.10.015_bib35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00019053-200725120-00005","article-title":"Atorvastatin: A pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events","volume":"25","author":"Plosker","year":"2007","journal-title":"Pharmaco Economics."},{"key":"10.1016\/j.clinthera.2009.10.015_bib36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-006-0561-4","article-title":"Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: Results from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"50","author":"Raikou","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2009.10.015_bib37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200826040-00005","article-title":"An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes","volume":"26","author":"Ramsey","year":"2008","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2009.10.015_bib38","first-page":"9","article-title":"Cost effectiveness of HMG-CoA reductase inhibition in Canada","volume":"8","author":"Russell","year":"2001","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.10.015_bib39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.amjcard.2003.06.009","article-title":"Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes","volume":"92","author":"Schwartz","year":"2003","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.10.015_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321001-00002","article-title":"An eco nomic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)","volume":"21","author":"Smith","year":"2003","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2009.10.015_bib41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00019053-200523030-00007","article-title":"A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain [published correction appears in PharmacoEconomics. 2006;24:106]","volume":"23","author":"T\u00e1rraga-L\u00f3pez","year":"2005","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2009.10.015_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10198-008-0126-1","article-title":"Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study","volume":"10","author":"Taylor","year":"2009","journal-title":"EurJ Health Econ"},{"key":"10.1016\/j.clinthera.2009.10.015_bib43","first-page":"144","article-title":"Cost effectiveness of statin therapy for the primary prevention of coronary heart disease","volume":"99","author":"Walshe","year":"2006","journal-title":"Ir Med J"},{"key":"10.1016\/j.clinthera.2009.10.015_bib44_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clinthera.2009.10.015_bib44_2","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clinthera.2009.10.015_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.317.7155.405","article-title":"Decision analysis and the implementation of research findings","volume":"317","author":"Lilford","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2009.10.015_bib47","series-title":"Critical Appraisal About Clinical Usefulness and Cost-Effectiveness of Listed Hyperlipidemia Drugs [in Korean]","article-title":"Cost of cardiovascular disease","year":"2007"},{"key":"10.1016\/j.clinthera.2009.10.015_bib50","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1161\/CIRCULATIONAHA.105.607499","article-title":"Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults","volume":"114","author":"Wu","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2009.10.015_bib51","series-title":"HIRA Technical Report 2006\u20132008","article-title":"Construction of National Surveillance System for Cardiovascular and Cerebrovascular Diseases","year":"2006"},{"key":"10.1016\/j.clinthera.2009.10.015_bib52","series-title":"IMS Technical Report 2008\u201302","article-title":"IMS Sales Audit: Market share 2008 MAT, 2Q08","year":"2008"},{"key":"10.1016\/j.clinthera.2009.10.015_bib54","series-title":"KIHASA Technical Report 2008\u20132026","article-title":"Korean Utility Weights for Major Chronic Diseases","author":"Kang","year":"2008"},{"key":"10.1016\/j.clinthera.2009.10.015_bib55","first-page":"673","article-title":"Adherence with single-pill amlodipine\/atorvastatin vs a two-pill regimen","volume":"4","author":"Patel","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2009.10.015_bib56","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/hs0901.094253","article-title":"Long-term survival and causes of death after stroke","volume":"32","author":"Br\u00f8nnum-Hansen","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2009.10.015_bib57","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0895-4356(01)00405-X","article-title":"Survival and cause of death after myocardial infarction: The Danish MONICA study","volume":"54","author":"Br\u00f8nnum-Hansen","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2009.10.015_bib58","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.clinthera.2008.12.003","article-title":"Long-term persistence with statin therapy: A nationwide register study in Finland","volume":"30","author":"Helin-Salmivaara","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.10.015_bib59","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.10.015_bib60","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0149-2918(01)80152-1","article-title":"Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes","volume":"23","author":"Conlin","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.10.015_bib61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmaco-Economics"},{"key":"10.1016\/j.clinthera.2009.10.015_bib62","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"10.1016\/j.clinthera.2009.10.015_bib63","series-title":"National Health Insurance Statistical Yearbook","year":"2006"},{"key":"10.1016\/j.clinthera.2009.10.015_bib64","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.apmr.2007.12.045","article-title":"Disparities in antihypertensive medication adherence in persons with disabilities and without disabilities: Results of a Korean population-based study","volume":"89","author":"Park","year":"2008","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.clinthera.2009.10.015_bib65","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ijcard.2007.04.114","article-title":"Antihypertensive drug medication adherence and its affecting factors in South Korea","volume":"128","author":"Park","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2009.10.015_bib66","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1185\/03007990802138731","article-title":"Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: The Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study","volume":"24","author":"Kim","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2009.10.015_bib67","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00019053-200624110-00002","article-title":"Recent developments in decision-analytic modelling for economic evaluation","volume":"24","author":"Weinstein","year":"2006","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2009.10.015_bib68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","article-title":"Cardiovascular disease risk profiles","volume":"121","author":"Anderson","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2009.10.015_bib69","first-page":"272","article-title":"Primary and subsequent coronary risk appraisal: New results from the Framingham study [published correction appears in Am Heart J. 2002;143:21]","volume":"139","author":"D\u2019Agostino","year":"2000","journal-title":"Am Heart J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T15:40:01Z","timestamp":1685202001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809003725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0149291809003725"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.10.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}